We can’t show the full text here under this license. Use the link below to read it at the source.
Glucagon-like peptide-1 receptor agonists, inflammation, and kidney diseases: evidence from Mendelian randomization
Links between glucagon-like peptide-1 receptor activators, inflammation, and kidney disease from genetic evidence
AI simplified
Abstract
Genetically proxied GLP1R agonist is associated with a decreased risk of diabetic nephropathy ( = 0.72) and IgA nephropathy (OR = 0.58).
- GLP1R agonists may reduce the risk of diabetic nephropathy and IgA nephropathy based on genetic evidence.
- The odds ratio for diabetic nephropathy suggests a significant association with a decreased risk.
- For IgA nephropathy, a similar significant decrease in risk was observed.
- An indirect effect of GLP1R agonists on IgA nephropathy was identified through a specific immune signaling pathway.
- The mediated proportion of this indirect effect was 34.27%, indicating a notable relationship.
AI simplified
Key numbers
0.72
Decrease in Risk
from meta-analysis of discovery and validation cohorts.
0.58
Decrease in Risk
from meta-analysis of discovery and validation cohorts.
34.27%
Mediated Proportion by
Proportion of total effect mediated by .